Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa in anemic cancer patients receiving chemotherapy
NCT00270166Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Feb 1995
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, double-blind trial of epoetin alfa in anemia (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Proportion of patients without transfusion after first month at 12 weeks. Started Feb 1995; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00270166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270166.